YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company, announced today that preliminary findings from its ongoing Phase II dermatological study show topical treatment with AVR118 appears to have clinical activity in reducing inflammation and redness associated with surgical incisions or dermatologic dermabrasion.
